Bimekizumab for Psoriasis: Raising the Bar in Treatment

Abstract

Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferation of keratinocytes and immune dysregulation. The advent of biologic therapies has revolutionized its management; however, challenges such as loss of efficacy over time, treatment-resistant areas like the nails and scalp, and comorbid conditions complicate treatment strategies.

Bimekizumab, a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, has demonstrated superior efficacy in managing moderate to severe plaque psoriasis. In the BE RADIANT phase 3b trial, patients receiving bimekizumab achieved higher rates of skin clearance compared to those treated with secukinumab, another IL-17A inhibitor. At Week 48, 74.8% of patients treated with bimekizumab achieved complete skin clearance (PASI 100), compared to 52.8% of those receiving secukinumab [1]. This superiority was maintained over a three-year period, indicating sustained long-term benefits [2]. The dual inhibition of IL-17A and IL-17F by bimekizumab is believed to contribute to its enhanced effectiveness.

A significant concern with biologic treatments is the potential loss of efficacy over time, necessitating changes in therapy. Studies have reported diminished responses with agents like secukinumab, another anti-IL-17 blocker, leading to treatment discontinuation or modification. If there has been a secondary loss of efficacy during treatment, i.e., the drug with the same target was effective previously, it is worth trying another molecule with the same target. The sustained efficacy of bimekizumab over extended periods offers a potential solution to this issue, providing consistent disease control and reducing the need for frequent therapeutic adjustments [3].

Psoriasis affecting the nails and scalp presents unique treatment challenges due to the difficulty of delivering therapies effectively to these sites. These areas often exhibit resistance to standard treatments and significantly impact patients' quality of life. While specific studies on bimekizumab's efficacy in nail and scalp psoriasis are limited, its robust anti-inflammatory effects suggest potential benefits in these difficult-to-treat regions [4].

Systemic treatment of psoriasis patients with comorbidities is always a challenge for the treating physician. Traditional systemic agents, such as methotrexate and cyclosporine, are often contraindicated in chronic kidney disease due to nephrotoxicity or because the drugs are eliminated through the kidneys. Biologic therapies, including bimekizumab, offer a safer alternative for psoriasis patients with renal impairment, as the kidneys do not primarily metabolize them and have a favorable safety profile [5].

Bimekizumab represents a superior therapeutic option for patients with moderate to severe plaque psoriasis, offering sustained efficacy and addressing challenges associated with traditional biologic therapies. Its potential benefits in treatment-resistant areas and suitability for patients with comorbidities further underscore its value in comprehensive psoriasis management.

The author declares no conflicts of interest.